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England is predicted to rise, and it is unclear whether treatment
at current levels will be able to avert this. The aim of this study
was to estimate the number of people with chronic HCV infection
in England that are treated and assess the impact and costs of
increasing treatment uptake.
Methods: Numbers treated were estimated using national data
sources for pegylated interferon supplied, dispensed, or pur-
chased from 2006 to 2011. A back-calculation approach was used
to project disease burden over the next 30 years and determine
outcomes under various scenarios of treatment uptake.
Results: 5000 patients were estimated to have been treated in
2011 and 28,000 in total from 2006 to 2011; approximately
3.1% and 17% respectively of estimated chronic infections. With-
out treatment, incident cases of decompensated cirrhosis and
hepatocellular carcinoma were predicted to increase until 2035
and reach 2290 cases per year. Treatment at current levels should
reduce incidence by 600 cases per year, with a peak around 2030.
Large increases in treatment are needed to halt the rise; and with
more effective treatment the best case scenario predicts inci-
dence of around 500 cases in 2030, although treatment uptake
must still be increased considerably to achieve this.Journal of Hepatology 20
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The Health Protection Agency estimated that in 2005, 161,000
adults in England were chronically infected with hepatitis C
(HCV) [1]. National data sources show that HCV-related liver
disease is increasing, with predictions indicating that this trend
will continue for at least the next 10 years [2,3]. This will place
a substantial burden on healthcare services and result in a signif-
icant reduction in lifespan for many infected individuals.
Treating HCV infected patients presents a considerable chal-
lenge for the National Health Service (NHS) as many infections
are undiagnosed [3] and treatment is not successful in every case
[4–8]. A significant proportion of the infected population, includ-
ing people who inject drugs and minority ethnic populations, are
‘hard to reach’ and service provision has been shown to vary geo-
graphically and not always be configured to allow easy access to
these groups [9]. Despite the availability of NICE recommended
therapies for some years [4,5] the treatment of patients with
HCV in England remains sub-optimal. Successful treatment
increases health and quality of life and reduces premature
mortality from liver disease, which is a specific government tar-
get for improvement and public health outcome [10,11]. Improv-
ing access to hepatitis C treatment services will also help to
reduce health inequalities as many of those infected belong to
marginalised groups of society [12].14 vol. 61 j 530–537
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The Government’s 2004 Hepatitis C Action Plan for England
[13] called for ‘high-quality services for the assessment and treat-
ment of all patients with hepatitis C be co-ordinated and accessi-
ble across the country’. However, countrywide assessment of
service provision has not been possible over recent years because
national surveillance systems do not monitor referral and treat-
ment. Consequently, progress towards achieving the provision
required by the 2004 action plan is not easily assessed and it
remains difficult to evaluate any impact on the future burden
of hepatitis C. This study aims to provide a national estimate of
the number of people who have received HCV treatment using
a number of alternative data sources, and to assess the impact
and associated costs of various treatment strategies on the future
burden of HCV-related disease in England. Results from this work
are intended to raise awareness of the existing level of treatment
coverage in England, the consequent future burden of hepatitis C
and the likely impact of increased treatment on this burden. This
awareness is crucial to inform commissioning of treatment ser-
vices and ensure that they are configured in a way that allows
easy access to those groups that need them most.Materials and methods
The analysis consists of three steps: (1) estimating numbers of patients treated in
the period 2006–2011 via datasets relating to total volumes of drugs used for
hepatitis C treatment; (2) applying a back-calculation approach to estimate the
current disease-stage and age distribution of the infected population and progres-
sion probabilities within a health-state model; and (3) using the estimated model
to predict future burden under different scenarios for the proportion of those
with chronic infection treated each year.
Data on drugs used for treatment of hepatitis C
Three data sources representing volumes of drugs used to treat HCV were used to
estimate the number of people treated annually for HCV.
(i) Ex-factory sales to NHS hospitals
The use of ex-factory sales data was negotiated with the drug companies who
were sole suppliers of the components of anti-HCV combined therapy: (Roche:
peginterferon alfa-2a Pegasys and the ribavirin Copegus; Schering Plough (now
Merck Sharp & Dohme) peginterferon alfa-2b Viraferon-Peg and the ribavirin
Rebetol). The companies provided data for the years 2006–2011 for hospitals
and dispensing pharmacies in England.
(ii) Pharmex – National usage by primary buying groups
These data consist of NHS hospital-sector annual usage of the components of
combined therapy by primary buying groups in England – largely equivalent to
Regions. The estimates are derived from data collected via the DH Commercial
Medicines Units’ Pharmex system [14] (covering 97% of the constituent NHS
Trusts).
(iii) IMS HEALTH Hospital Pharmacy Audit Index (HPAI)
IMS data on the amount of the components of anti-HCV combined therapy dis-
pensed in 2006–2011 were used. These data were supplied via drug companies
by arranging third party data sharing agreements. IMS collect information from
97% of English acute hospitals on all medicines dispensed in hospitals.
Data from all three sources were used to calculate the number of weeks of
treatment in 2006–2011, based on recommended weekly doses of pegylated
interferon for chronically infected patients. Data on ribavirin were also used for
validation, although calculations require more assumptions due to weight-
specific dosing and adjustment. The NICE template definitions for the length of
treatment used by patients with HCV genotypes 1 and 4, or 2 and 3 [5], and
the distribution of these genotypes in England [15] were used to calculate the
average number of weeks’ treatment required for each patient. Briefly, 55% of
patients are assumed to have genotypes 1, 4, 5, or 6; of whom 46% discontinue
early at 12 weeks, with the remainder receiving 48 weeks of treatment; thoseJournal of Hepatology 201with genotypes 2 and 3 receive 24 weeks of treatment [5]. We assessed sensitiv-
ity to these assumptions using values of 37% and 55% discontinuations for geno-
types 1, 4, 5, or 6; and 20% and 50% discontinuation at 12 weeks for genotypes 2
and 3. The number of weeks dispensed, sold or prescribed divided by the average
number of weeks of treatment required was used to give estimates of the number
of patients treated in 2006–2011, obtained by averaging estimates from the three
different sources. Further details are available in Supplementary data, section
‘‘Calculation of the number of doses of pegylated interferon’’.
Back-calculation model
Analyses were based on previous work [2], which estimated the burden of HCV in
England via back-calculation, using data on disease end points and information
on progression rates [16]. A multistate model was constructed to represent the
evolution of HCV infection through disease states: acute infection, infection clear-
ance, mild chronic HCV, moderate chronic HCV, cirrhosis, decompensated cirrho-
sis (end-stage liver disease; ESLD), hepatocellular carcinoma (HCC), and death.
Hospital episode statistics (HES) data on ESLD and HCC; and Office of National
Statistics (ONS) data on HCC mortality were used as disease endpoints. Both data-
sets were grouped into 10-year age bands prior to analysis. The number of hospi-
tal episodes for ESLD (defined by ICD10 codes for ascites (R18), bleeding
oesophageal varices (I850); hepato-renal syndrome (K767), hepatic encephalopa-
thy or hepatic failure (K704, K720, K721, K729)) and HCC (ICD10 code C22.0)
were available from HES for the period April 1995 to March 2009. Multiple epi-
sodes for the same individual within a year were identified and excluded using
the unique HES ID number. Death entries with any mention or code for primary
liver cancer or HCC (ICD9 155.0, ICD10 C22.0) and any mention or code for hep-
atitis C infection were included for the period 1996–2009; and the observed data
were corrected for under-reporting within the model [2].
Information on the probabilities of progressing through the disease states
was taken from the literature as in Sweeting et al. [2] and combined with the
above data to derive estimates of the underlying incidence of infection and the
number of individuals in each disease state over time. Moreover, an estimate of
the overall adult anti-HCV prevalence was used to constrain the total number
of infected individuals in 2005 [1]. Resulting estimates are then consistent with
current estimates of the infected population size and observed data on ESLD,
HCC, and HCC mortality. Further details are available in Supplementary data,
section ‘‘back-calculation model’’.
Burden projection
The numbers of individuals in each health state in 2012 and progression proba-
bilities estimated by the back-calculation model were used to generate future
projections, based on the assumption that the progression probabilities remain
the same over time. We also assumed continued incidence of 5000 infections
(HCV antibody positive) per year, based on the back-calculation estimate for
the period 2006–2010. This estimate is imprecise, but broadly consistent with
evidence on the population size of injecting drug users [17,18], previous esti-
mates of the proportion susceptible [1] and the force of infection applied to this
population [19], from which the bulk of new infections arise. This pragmatic
assumption leads to a relatively stable overall prevalence of chronic infections
(in the absence of treatment) between 2010 and 2020 that then declines slowly
by around 20% by 2040.
During each year, a proportion of those in chronic, moderate, and cirrhotic
states are assumed to be treated; and may then achieve sustained viral response
(SVR) with age, disease state, and genotype-specific probabilities estimated from
an observational cohort of patients in clinical practice, which should broadly
reflect the HCV-infected population in the UK [20]. These probabilities are based
on intention to treat analysis, and hence discontinuation and adherence issues are
assumed to be incorporated in the overall response rate. Briefly, those aged 40
with non-1 genotype have SVR probabilities of 0.82, 0.70, and 0.40 for mild, mod-
erate, and cirrhosis states; while those with genotype 1 have probabilities of 0.57,
0.37, and 0.11. Those 10 years younger/older have probabilities of SVR around
0.05–0.10 higher/lower; and in the absence of information on probabilities in
other age groups, we assumed younger/older groups to be the same as the youn-
gest/oldest known group. Upon achieving SVR, patients in mild and moderate
states are no longer at risk of progressing further and have comparable mortality
to the general population; although higher rates were assessed in sensitivity
analyses, with a five-fold increase in those aged 20–59. Those with compensated
cirrhosis are assumed to still be at risk of further progression, but at a reduced
rate [21]. Those failing to respond to treatment continue to progress through
health states as before, and are not treated again. Progression through health
states and treatment is shown in Fig. 1. We also assumed some of those with ESLD4 vol. 61 j 530–537 531
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Fig. 1. Health-state model describing the natural history of hepatitis C, treatment states, followed by failure or sustained viral response, liver transplants, and
death. Note that in all states death by natural causes may occur; this has not been shown for clarity. Shaded circles denote observed data (up to 2010). SVR, sustained viral
response; HCC, hepatocellular carcinoma.
Research Articleand HCC receive liver transplants, at a fixed rate of 2.5% and 10% per year respec-
tively, based on national transplant data and current estimates of HCV burden [3].
Annual post-transplant survival probabilities for HCV patients were taken from
Thuluvath et al. [22]. Further details are given in Supplementary data, section
‘‘back-calculation model’’.
Treatment scenarios
We based estimates of overall proportions treated annually on the three sources
of pegylated interferon doses for 2006–2011, assuming the same level in 2012 as
2011; and approximately 11,200 treated during 2002–2005 [23], with the effect
of treatment before this assumed to be negligible. As individuals are more likely
to be diagnosed and treated as disease progresses, we assigned greater propor-
tions treated in more advanced disease states, with 2%, 3%, and 6% of mild chronic
HCV, moderate chronic HCV, and compensated cirrhosis patients treated annually
for our baseline scenario, based on data from the Trent cohort [20]. Treatment
then continues at 2012 levels, or is increased in alternative scenarios from
2013 onwards. The different scenarios are summarised in Table 1.
The potential impact of new and future treatments was also assessed. Recent
studies on the direct acting antivirals (DAAs) Boceprevir [24,25] and Telaprevir
[26] have indicated that SVR rates can be greatly improved in those with the more
difficult to treat genotype 1 infection. In addition, many new drugs are in devel-
opment or likely to be approved soon that show promise of delivering SVR rates
close to 100% with interferon-free regimens regardless of genotype [27,27–29],
although the efficacy in those with cirrhosis has not been well evaluated, and
early reports indicate SVR rates may be lower [30]. We assume that new treat-
ments will be gradually introduced such that the average probability of SVR in
a treated patient will increase steadily from those reported in Thomson [20] to
an optimum level in 2018, with 90% SVR in those with mild or moderate chronic
HCV and 60% in those with compensated cirrhosis. We assessed the impact of
such treatments under scenarios 3–7 (Table 1).
The impact of different scenarios on the numbers of individuals in each health
state was assessed, focussing on ESLD/HCC incidence over the next 30 years. We
examined the estimated number of cases under each scenario, and differences in
comparison with the base case (either current levels, or no treatment). Costs asso-
ciated with each state [31] were applied to the resulting numbers in order to
determine the additional cost of implementing different treatment scenarios,
and the cost per case of ESLD/HCC averted. The latter is an incremental
comparison according to the standard formula:532 Journal of Hepatology 201ICER ¼ ðC2  C1Þ=ðE1  E2Þ
where Ci and Ei are the cost and number of events respectively under scenario
i, and scenario 2 is being compared to the base case scenario 1. Results are pre-
sented in UK pounds sterling. Healthcare costs were adjusted according to the
hospital community health services pay and prices index [32], and we examined
the impact of discounting events and costs according to NICE guidelines [33]. We
examine the costs of standard treatment with pegylated interferon and ribavirin
only, given the rapidly changing landscape of hepatitis C treatment [29] and
uncertainty of costs for new drugs. Further details on the burden model and
assumed costs are given in Supplementary data, section ‘‘costs’’.
The back-calculation model was implemented in a Bayesian framework using
WinBUGS [34]. Predictions are a function of the estimated parameters combined
with scenario inputs, and are therefore obtained via a process akin to probabilistic
simulation. Resulting quantities of interest reflect uncertainty in the information
used, which is expressed via credible intervals (CrI), the Bayesian equivalent of a
95% confidence interval. To assess the robustness of our conclusions and deter-
mine factors driving the results, we varied the parameters in the model in sensi-
tivity analyses (one factor at a time), including different rates of SVR, disease
progression and background mortality; different proportions treated in each dis-
ease state; and cost of drugs.Results
Trends in treatment levels
The estimated number of HCV-positive patients receiving combi-
nation therapy based on pegylated interferon sold, purchased,
and dispensed 2006–2011 gave similar estimates (Fig. 2). In
2006, sufficient pegylated interferon was sold, purchased or dis-
pensed to treat an average of 3234 individuals. Treatment levels
rose annually from 3234 in 2006 to 5316 in 2010, but the annual
increase slowed over time and decreased between 2010 and 2011
(Fig. 2).
Sensitivity analyses for a discontinuation rates in genotype 1,
4, 5, or 6 of 37% and 55% resulted in a ± 6% difference in estimated4 vol. 61 j 530–537
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Fig. 3. Annual numbers treated under different scenarios. Current levels:
approximately 3% of previously untreated individuals are treated annually; 50%
and 100% increase steadily increases annual treatment rates such that numbers
are 50% and 100% higher by 2023; gradual and rapid complete coverage increases
treatment such that all previously untreated individuals are given treatment
within 30 and 15 years respectively.
Table 1. Treatment scenarios examined in the burden projection model.
Scenario Description
1. No treatment Hypothetical projection of future burden in the absence of past and future treatment
2. Past treatment Hypothetical projection of future burden in the absence of future treatment
3. Current (baseline scenario) Treatment levels continue at 2%, 3% and 6% for mild, moderate and cirrhosis
4. Increase 1 (50%) Treatment rates double over the next 10 years, resulting in a 50% increase in numbers treated 
annually in 2023.
5. Increase 2 (100%) Treatment rates triple over the next 10 years, resulting in a 100% increase in numbers treated 
annually in 2023.
6. Gradual complete coverage Treatment rates increase as above (5), then continue to rise from 2023 until 100% coverage is 
achieved in 2043.
7. Rapid complete coverage Treatment rates rise rapidly from 2013, with up to 30,000 per year treated and 100% coverage 
achieved in 15 years.
Note: all increases in treatment over time are via a linear increase in the annual proportion treated.
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Fig. 2. Numbers of HCV-positive patients receiving combination therapy
based on pegylated interferon sold, purchased and dispensed 2006–2011.
Average numbers from the three data sources and percentage annual change in
parentheses. Sources: 1Outlet Data on sales of pegylated interferon supplied by
Roche and Merck, Sharpe & Dohme Ltd, 2006–2011. 2IMS SCM Data on pegylated
interferon dispensed, Published Feb 2012, showing units to hospital outlets,
2006–2011. 3Pharmex Data, on interferon purchased, 2006–2011, supplied by the
Department of Health’s Commercial Medicines Unit.
JOURNAL OF HEPATOLOGYnumbers. If 20% of those with genotypes 2 and 3 also discontinue
at 12 weeks, estimated numbers treated are 5% higher; if this rate
were 50%, numbers treated are 13% higher.
Future burden of HCV and impact of treatment
Fig. 3 shows the numbers treated under current levels, and for
the four scenarios of increased treatment (4–7). Under current
treatment levels the number treated each year decreases over
time as the pool of untreated individuals declines, as the assumed
level of incidence is not high enough to maintain current preva-
lence. Under the two scenarios for a gradual increase over the
next 10 years, numbers treated are assumed to rise from 5000
per year to around 7500 and 10,000 respectively by 2023, before
stabilising at a fixed proportion treated; again, numbers treated
fall off as the pool of untreated individuals decreases. Scenario
6 assumes that over 30,000 individuals are treated in 2014, with
the proportion treated annually remaining high. The pool of
untreated individuals decreases quickly however, so that the very
high numbers treated are not sustained for long.Journal of Hepatology 201Fig. 4 shows the predicted incidence of HCV-related ESLD and
HCC over the next 30 years according to different treatment strat-
egies. In the absence of any treatment, annual incidence would be
predicted to rise to a peak of 2290 (95% CrI 2000–2750) in 2035.
Treatment between 2006 and 2012 was predicted to have some
impact on future burden (predicted incidence: 2080 (95% CrI
1820–2520) in 2035), but must continue in order to make a sig-
nificant impact. By 2035, annual incidence of HCV-related ESLD/
HCC under current treatment levels was predicted to be 640 (95%
CrI 550–760) cases fewer than without treatment. Increasing
treatment from current levels was predicted to reduce incidence
by a further 180 or 290 cases per year by 2035 with a 50% and
100% increase respectively. However, the gains made by increas-
ing treatment are relatively long-term unless very large numbers
are treated immediately; increases in treatment were predicted
to halt the rise in incidence more quickly, but only by rapidly
increasing to nearly complete coverage can the predicted rise in
incidence of HCV-related ESLD and HCC be halted in the near
future.
Introduction of more effective treatments was predicted to
have a major impact on future burden, with treatment at current
levels preventing approximately the same number of incident
ESLD/HCC as a 100% increase in standard treatment; and dou-
bling treatment levels with the more effective treatments having
more impact than rapid complete coverage of standard4 vol. 61 j 530–537 533
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Fig. 4. Predicted annual incidence of HCV-related end-stage liver disease and
hepatocellular carcinoma (ESLD/HCC) over the next 30 years according to the
implementation of different treatment scenarios. Left panel shows different
levels of treatment using current regimen; right panel using future treatments
with increased response rates. Current levels: approximately 3% of previously
untreated individuals are treated annually; 50% and 100% increase steadily
increases annual treatment rates such that numbers are 50% and 100% higher by
2023; gradual and rapid complete coverage increases treatment such that all
previously untreated individuals are given treatment within 30 and 15 years
respectively.
Research Articletreatment. Despite these improvements, it is some time before
incidence of ESLD/HCC is reduced by a substantial level, even
when combined with a large increase in coverage: the gradual
and rapid complete coverage scenarios with more effective treat-
ment predicted annual incidence of 620 (95% CrI 540–760) and
490 (95% CrI 430–580) respectively in 2035.
Cost of treatment
The total cost of maintaining current treatment levels (3%) with
pegylated interferon and ribavirin (or a regimen of similar cost)
over the next 30 years was estimated to be £910 million (95%
CrI 730–1210) greater than no treatment; this being the differ-
ence in total healthcare and treatment costs between the two
scenarios. Increasing treatment to 50% and 100% more patients
treated within 10 years results in an additional total cost of
£460 million (95% CrI 380–600) and £740 million (95% CrI
610–970) respectively over the next 30 years. The cost per inci-
dent ESLD/HCC case averted was estimated to be £128,000 (95%
CrI 110,000–152,000) for a 50% increase; and very similar for a
100% increase and rapid complete coverage at £126,000 and
£111,000 respectively. It should be kept in mind that the results
above assume the same SVR rates and costs over time and do no
incorporate discounting. Assuming a discount rate of 3.5%
increases the cost per case averted to £169,000, reflecting that
treatment costs tend to be incurred in the short-term whereas
the reduction in ESLD/HCC occurs later in time. With a discount
rate of 1.5%, which NICE suggests when health benefits may be
sustained over a long period, the cost per case averted was
£143,000.
The total additional cost for implementing rapid complete
coverage was estimated at £1460 million (95% CrI 1170–1890)
over the next 30 years. These are substantial costs; however,534 Journal of Hepatology 201the total healthcare cost of the HCV-infected population over
the next 30 years under current treatment levels was estimated
to be £4680 million (95% CrI 3770–5900). Therefore, although
treatment costs are substantial, they are still relatively small
compared to the total cost of disease burden.
Sensitivity analyses
We assessed the sensitivity of our results to changes in parame-
ter values and assumptions, using 100% increase vs. current
treatment for comparisons. Change in progression rates had a
large effect: with 50% faster progression between each state the
predicted disease burden is nearly doubled, but treatment then
has more impact as a greater number of ESLD/HCC cases are pre-
vented, with a cost per case averted of £66,000 compared to
£126,000 for the base case. Conversely, 50% slower progression
nearly halves the predicted burden, and the cost per case averted
is therefore far higher at £254,000. Changes in SVR rates (assum-
ing the same cost of treatment) have relatively little impact on
predicted disease burden, given the relatively low levels of treat-
ment for these scenarios, but gave a cost per case averted of
£105,000 if SVR rates are 50% higher (an odds ratio of 1.5) and
£153,000 if SVR rates are 50% lower. Higher background mortality
(five times higher in those aged 20–59) reduces the prediction of
future burden, as more people die from other causes before
reaching ESLD/HCC states, reducing the peak burden to 1100
cases per year. The cost per case averted therefore increases to
£163,000 under this scenario. As there is a delay between treat-
ment and prevention of ESLD/HCC, using a longer time window
also reduces the cost per case averted, at £45,000 over a 70 year
window, with a greater proportion of prevented cases post-2043.
More details of sensitivity analyses are given in Supplementary
data, section ‘‘sensitivity analyses’’.Discussion
Principal findings
Supply, dispensing and purchasing data suggest that around
28,000 patients were treated from 2006 to 2011; approximately
17% of those estimated to have chronic hepatitis C infection in
England in 2005 [1]. The number treated increased from 2006
to 2010, but has not increased subsequently. Treatment for HCV
with pegylated interferon and ribavirin has been introduced rel-
atively recently; so far, treatment levels have been too low (and
end points too distant) to assess the impact on disease burden,
as has been done, for example, for HIV; and government action
plans were only issued in 2004 [35]. We therefore assessed the
potential impact of treatment via projections of future burden,
based on knowledge of disease progression and response to treat-
ment. These analyses provide a strong argument for increasing
levels of treatment, ideally as soon as possible.
Strengths and weaknesses
The use of dispensing and purchasing data to estimate trends in
numbers treated has some limitations. Pegylated interferon
monotherapy may be prescribed to a small number of HCV posi-
tive patients who have ribavirin intolerance. Pegylated interferon
alfa-2a is also prescribed for patients with chronic hepatitis B4 vol. 61 j 530–537
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infection; however, this is likely to account for only a small num-
ber of patients: the NICE costing template for hepatitis B used
estimates of 154 patients treated with pegylated interferon
alfa-2a in 2006 [36]. Estimates based on ribavirin data gave
slightly lower numbers, but agreed well with the patterns
obtained from the pegylated interferon data. Neither Pharmex
nor IMS data cover all hospitals in England, although only two
of the nine hospitals that do not contribute data to IMS or Phar-
mex were listed as potential treating centres for HCV. Finally,
average treatment lengths are based on those reported by NICE
[5] and in the absence of further information we do not know
how accurate these are in the general population. Early stopping
in genotype 1 patients are accounted for in the NICE template,
but all of those with genotypes 2 and 3 are assumed to complete
a 24 week course. However, sensitivity analyses assuming as
much as 50% with genotypes 2 and 3 and 55% of other genotypes
stopping at 12 weeks do not change our estimates by more than
20% (Supplementary data, section ‘‘Calculation of the number of
doses of pegylated interferon’’). Our results should therefore
reflect broad trends and the general level of current treatment.
The projection of future burden in England is based on the
best evidence currently available. The back-calculation model
uses estimates of disease progression from the literature as prior
information, and this information is combined with the observed
data on disease endpoints and current best estimates of overall
disease prevalence. Transition rates and intervention effects for
treatment were obtained from population-based studies in the
UK, and we have used age-specific transition rates to address het-
erogeneity, as recommended in Siebert et al. [37]. Therefore the
model produces results that are consistent with the overall pic-
ture of the natural history and disease burden of hepatitis C in
England today. However, it must be borne in mind that our
results rest on the assumption that the model structure is correct
and the data we have used are not subject to systematic bias;
therefore the relatively narrow credible intervals may give an
over-optimistic impression of confidence in these results. In
terms of validation, the model fits the national data well and,
for instance, resulting progression probabilities are similar to
those of the UK cohort studies upon which they are based (the
model is internally consistent). However the model has not been
formally externally validated. As all relevant national data have
been used to fit the model, any external validation would need
to be carried out using data from other countries or settings. This
is outside the scope of this work, although we are actively looking
for such opportunities. However, an informal assessment shows
that our estimated progression probabilities are comparable to
studies in France and the US [38,39], with a 20-year probability
of progressing to cirrhosis of 14% in 40–49 year olds. Some stud-
ies have reported higher rates [40]; although these vary greatly
depending on setting [41], alcohol use [38], and duration of infec-
tion [41] and with an apparent difference in rates by country [23].
These issues are further discussed in Supplementary data, section
‘‘back-calculation model’’.
Projections have been derived under some simplifying
assumptions. Incidence has been assumed constant, which could
change substantially in the future, particularly if successful treat-
ment results in decreased transmission of HCV [42]. However, as
the main focus is on ESLD/HCC occurring over the next 30 years,
changes in incidence will have comparatively little impact on dis-
ease endpoints within this time frame. The model also does not
include re-infection, leading to an over-estimate of the numberJournal of Hepatology 201remaining clear of infection in this cohort over time; although
conversely, the possibility of re-treating those who fail to achieve
SVR has also not been considered. Further assumptions are that
the progression probabilities will not change over time. This
could potentially impact on future burden: sensitivity analyses
indicate that the predicted burden is highly dependent on pro-
gression probabilities. Another area of uncertainty is mortality
from other causes; which, if higher, would result in less HCV-
related morbidity. It was not possible to account for differing pro-
gression rates due to alcohol and other factors: this would
require better information from cohort studies and remains an
area of future research.
Our study contains elements of cost-effectiveness analysis,
but we have not applied discounting in our main results, where
future benefits (and costs) are down-weighted. This is because
our main aim is to enumerate absolute costs and increases using
the same type of treatment, rather than comparing ‘‘competing’’
strategies or technologies. Discounting results in a greater cost
per ESLD/HCC case averted; this is because disease progression
is typically slow; and reductions in ESLD/HCC from increasing
treatment is a long-term goal.
Finally, we have not considered the additional costs of
increasing treatment uptake in terms of increased case finding,
health promotion campaigns, and improved infrastructure that
might be required. These costs may be substantial to achieve very
high levels of coverage; although improved treatment options,
especially easy-to-tolerate interferon-free regimes, seem likely
to naturally result in increased uptake.
Implications for clinicians and policymakers
Supply, dispensing, and purchasing data suggest that treatment
of chronically HCV-infected individuals rose by 20% per year from
2006 to 2008, but has declined recently. Between 2006 and 2011
an estimated total of approximately 28,000 individuals have been
treated. These low treatment levels indicate that many individu-
als are failing to access appropriate management country-wide.
If the future burden of HCV-related disease is to be averted,
significant increases in treatment need to be achieved, and NICE
have recently issued guidance to ensure that more people at
increased risk of hepatitis C (and B) infection are offered testing
and treatment services [43]. While reorganisation of the NHS in
England poses a challenge to hepatitis C provision, particularly
for those marginalised groups of society who are most affected
by the virus, it also provides opportunities for better co-ordina-
tion of services; the development of integrated services that
reach into communities – whether based in primary care, drug
services, prisons or elsewhere – will be key for increasing access
to HCV treatment.
There are a number of new drugs under development with the
likely prospect of interferon-free regimes in the near future [27].
Achieving high cure rates has so far been hampered by treatment
regimes that are difficult to tolerate and have low SVR rates for
genotype 1 patients and those with advanced fibrosis. Although
DAAs offer an improvement in SVR rates, they have been associ-
ated with higher rates of adverse events [44] and are costly [45].
The introduction of safe, orally administered treatment that is
effective across genotypes could radically change the picture of
hepatitis C treatment today, as such drugs could be rolled out
in the community and achieve widespread coverage. Despite
the strong possibility that such treatments are on the way, it4 vol. 61 j 530–537 535
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remains to be seen whether the costs of these new treatments
will be acceptable. Exact costs of new drugs such as Sofosbuvir
are not yet available, but are likely to be high [46]. Given the costs
for treating large numbers of people even with standard treat-
ment, the total costs for new drugs will be significant. However,
this must be offset against savings in other healthcare costs, such
as the management of end stage liver disease and liver trans-
plant. The landscape of hepatitis C treatment is changing rapidly
and it seems an era of vastly improved treatment is on the way. In
the mean time however, disease burden is rising and there
remains a pressing need for infected patients to be treated as
soon as possible.
Final remarks
Monitoring treatment and treatment outcomes in patients with
HCV infection must be an ongoing process, especially with the
advent of new therapies [7,8,28]. This requires the availability
of regular and reliable estimates of the number living with HCV
infection and those who are receiving treatment. As such, there
is an urgent need for service providers to supply accurate infor-
mation on the numbers of individuals referred and treated, as
well as on the outcomes of treatment. These can then be used
with the type of models described here to estimate future disease
burden, which is essential for local planning of treatment and
care services. If the increases in cirrhosis and deaths from HCV-
related disease that have been predicted in England are to be
averted, commissioners will need to consider expanding provi-
sion of treatment in non-traditional settings, including primary
care, drug treatment settings and prisons. It is vital to make treat-
ment more accessible for those groups who need it most and
address the health inequalities that result from excess premature
deaths from HCV-related liver disease in marginalised
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